CLDN5 and major depressive disorder: A comprehensive understanding of CLDN-5 based TJs in the ECs and its regulation by pericytes and astrocytes should lead to novel drug targets to treat vascular-mediated dementia, schizophrenia and MDD and to reduce some of the pathologies of other CNS diseases.